课题基金 / 基金详情

Pathomechanisms in Facioscapulohumeral muscular dystrophy

Pathomechanisms in Facioscapulohumeral muscular dystrophy
面肩肱型肌营养不良症的病理机制
批准号:
MR/X001520/1
负责人:
Peter Zammit
金额:
$96.43万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

Peter Zammit的其他基金

相似基金

相关文献

中文摘要
翻译
如果了解症状背后的原因/机制,疾病可以得到更有效的治疗。对于肌营养不良症来说,导致缺陷的是基因或DNA的变化,而这些变化反过来又会导致蛋白质的变化。然而,对于这些缺陷是如何导致肌肉营养不良症典型的衰弱、进行性骨骼肌无力和消瘦的,人们通常知之甚少。人体中的每个细胞都含有相同的脱氧核糖核酸,这些脱氧核糖核酸被分成几个基因,每个基因都携带着制造蛋白质的指令(S):建造、维护和操作身体的分子。在特定的细胞类型中表达(活跃)的基因的选择,例如在肌肉纤维中,决定了产生哪些蛋白质。这赋予了细胞特殊的特性和功能。例如,特定的肌肉基因在皮肤细胞中不表达,反之亦然。面肩肩周肌营养不良症(FSHD)是无法治愈的。FSHD是由DNA特定区域的变化引起的,该变化导致一种名为DUX4的蛋白质的产生,这种蛋白质通常不存在于肌肉中。DUX4是一种“转录因子”,这意味着它可以通过结合其他基因的调节区来控制它们的表达,因此可以改变细胞制造的蛋白质的类型。因此,使骨骼肌有效运作的基因表达和蛋白质生产的精心协调模式被DUX4的存在扰乱了。这最终导致肌肉虚弱和消瘦。我们检测了表达FSHD和DUX4的肌肉细胞中基因表达的变化,并使用数学工具来了解哪些信号传递过程受到干扰。我们发现,控制线粒体生成和与线粒体功能相关的过程的途径受到抑制,例如处理代谢/呼吸的副产物,称为活性氧物种(导致氧化应激)。众所周知,FSHD肌肉细胞对氧化应激更敏感,最近的一项临床试验(Clinicaltrials.gov编号:NCT01596803)报告称,服用抗氧化剂可以改善FSHD患者的肌肉功能。肌肉新陈代谢得到仔细协调,以确保产生足够的能量,使肌肉从休息到进行剧烈运动始终有效地工作。这些系统在FSHD中受到干扰,但尚不清楚DUX4是如何做到这一点的。为了进行研究,我们将检测FSHD细胞和表达DUX4的细胞的新陈代谢速度(使用一种名为呼吸测量法的技术)、基因表达的变化(使用一种名为RNA测序的技术)和新陈代谢(使用一种名为核磁共振的技术)。这将使人们更好地了解FSHD的病因,长期目标是为FSHD找到新的、更有效的靶向疗法,以告知、支持和支持临床试验。
英文摘要
Diseases can be treated more effectively if the causes/mechanisms underlying the symptoms are known. For muscular dystrophy, the causative defect is changes in genes or DNA that in turn, produce changes to proteins. However, it is generally poorly understood how such defects result in the debilitating, progressive skeletal muscle weakness and wasting typical of muscular dystrophies. Every cell in the body contains the same DNA, which is divided into genes, each of which carries the instructions to make a protein(s): the molecules that build, maintain and operate the body. The selection of genes that are expressed (active) in a particular cell type, such as in a muscle fibre, dictate which proteins are made. This gives the cell its special characteristics and functions. For example, specific muscle genes are not expressed in skin cells, and vice-versa.Facioscapulohumeral muscular dystrophy (FSHD) is incurable. FSHD is caused by a change in a particular region of DNA that leads to production of a protein called DUX4, that is not normally present in muscle. DUX4 is a 'transcription factor' meaning that it can control the expression of other genes by binding to their regulatory regions, and so can alter the type of proteins that are made by a cell. Thus the carefully coordinated pattern of gene expression and protein production that enables skeletal muscle to function effectively is perturbed by the presence of DUX4. This ultimately leads to muscle weakness and wasting.We have examined gene expression changes in FSHD and DUX4-expressing muscle cells and used mathematical tools to understand which signalling process are perturbed. We found that pathways are suppressed that control generation of mitochondria and processes associated with mitochondrial function such as dealing with by-products of metabolism/respiration called reactive oxygen species (that cause oxidative stress). It is known that FSHD muscle cells are more sensitive to oxidative stress, and a recent clinical trial (clinicaltrials.gov number: NCT01596803) reported that administration of anti-oxidants, improved aspects of muscle function in FSHD patients.Muscle metabolism is carefully coordinated to ensure generation of enough energy to make muscle always work efficiently, from when resting to undergoing strenuous exercise. These systems are perturbed in FSHD but it is unclear how DUX4 does this. To investigate, we will examine the rate of metabolism (using a technique called respirometry), changes in gene expression (using a technique called RNA-Sequencing) and metabolism (using a technique called Nuclear magnetic resonance (NMR)) in FSHD cells and cells made to express DUX4. This will give a better understanding of the cause of FSHD, with the long-term aim of finding new and more effective targeted therapies for FSHD to inform, support and underpin clinical trials.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Understanding and Ameliorating perturbed signalling and pathogenesis in FSHD
  • 批准号:
    MR/S002472/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $49.02万
  • 财政年份:
    2019
  • 负责人:
    Peter Zammit
  • 依托单位:
Understanding and Ameliorating Pathogenesis in FSHD
  • 批准号:
    MR/P023215/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $47.32万
  • 财政年份:
    2017
  • 负责人:
    Peter Zammit
  • 依托单位:
Do lamin A/C and emerin mutations in satellite cells contribute to Emery-Driefuss muscular dystrophy?
  • 批准号:
    G0700307/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $51.5万
  • 财政年份:
    2007
  • 负责人:
    Peter Zammit
  • 依托单位:
海外基金